Withus Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Withus Pharmaceutical makes finished prescription medicines, including treatments for high blood pressure, high cholesterol, hardening of the arteries, bone and joint conditions, digestive disorders, infections, and central-nervous-system conditions, targeting the chronic diseases common in an ageing population.
Its products are distributed through a nationwide sales network to hospitals, clinics, and pharmacies across South Korea. Listed on KOSDAQ, South Korea's tech and small-cap board, the company earns the largest share of its revenue from cardiovascular medicines, with its cholesterol-lowering tablet Atoren (atorvastatin), a generic version of a widely used branded drug, as its leading product.
Summary is AI-generated and may contain errors · figures from DART filings
Alongside its own branded generics, the company also manufactures finished medicines on behalf of other pharmaceutical firms under contract manufacturing (CMO) arrangements, a segment it is actively expanding.
Withus Pharmaceutical in five facts
What does Withus Pharmaceutical do?
Withus Pharmaceutical makes finished prescription medicines, including treatments for high blood pressure, high cholesterol, hardening of the arteries, bone and joint conditions, digestive disorders, infections, and central-nervous-system conditions, targeting the chronic diseases common in an ageing population.
Where is Withus Pharmaceutical listed and in which sector?
Withus Pharmaceutical (Korean name: 위더스제약) trades under KRX code 330350 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Withus Pharmaceutical?
Its market capitalisation was US$68.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Withus Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Withus Pharmaceutical reported revenue of US$80.3M, operating profit of US$4.3M and net income of US$3.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 3.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.